Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1913 1
1947 1
1974 1
1992 1
2001 3
2002 1
2005 1
2006 1
2007 1
2008 3
2009 1
2010 5
2011 4
2012 6
2013 5
2014 8
2015 4
2016 4
2017 6
2018 7
2019 3
2020 6
2021 5
2022 3
2023 3
2024 6
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, Ballot J, Toomey S, O'Connor DP, Gallagher WM, Holmes FA, Espina V, Liotta L, Hennessy BT, O'Byrne KJ, Hasmann M, Bossenmaier B, O'Donovan N, Crown J. Collins DM, et al. Among authors: eustace aj. Clin Cancer Res. 2021 Feb 1;27(3):807-818. doi: 10.1158/1078-0432.CCR-20-2007. Epub 2020 Oct 29. Clin Cancer Res. 2021. PMID: 33122343 Free PMC article. Clinical Trial.
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis.
Crown J, Eustace AJ, Collins DM, Keane M, Coate L, Kennedy J, O'Reilly S, Kelly C, O'Connor M, Martin M, Murphy C, Duffy K, Walshe J, Gullo G, Mahgoub T, Alvarez-Iglesias A, Parker I, Donachie V, Teiserskiene A, Madden SF, Moulton B, O'Donovan N, Hennessy BT. Crown J, et al. Among authors: eustace aj. Acta Oncol. 2025 Jun 5;64:751-760. doi: 10.2340/1651-226X.2025.43143. Acta Oncol. 2025. PMID: 40468999 Free PMC article. Clinical Trial.
Epidemic gastro-enteritis.
EUSTACE A. EUSTACE A. Br Med J. 1947 Jan 25;1(4490):159. doi: 10.1136/bmj.1.4490.159. Br Med J. 1947. PMID: 20244694 Free PMC article. No abstract available.
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.
Milewska M, Cremona M, Morgan C, O'Shea J, Carr A, Vellanki SH, Hopkins AM, Toomey S, Madden SF, Hennessy BT, Eustace AJ. Milewska M, et al. Among authors: eustace aj. Ther Adv Med Oncol. 2018 Jan 9;10:1758834017746040. doi: 10.1177/1758834017746040. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29383036 Free PMC article.
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.
Roche S, Gaule P, Winrow D, Mukherjee N, O'Neill F, Conlon NT, Meiller J, Collins DM, Canonici A, Fawsi MI, Estepa-Fernández A, Madden SF, Crown J, O'Donovan N, Eustace AJ. Roche S, et al. Among authors: eustace aj. PLoS One. 2023 Mar 15;18(3):e0282512. doi: 10.1371/journal.pone.0282512. eCollection 2023. PLoS One. 2023. PMID: 36920947 Free PMC article.
86 results